 |
市場調查報告書
商品編碼
1832737
濕性視網膜病變治療藥市場(2025年)2025 Exudative Retinal Disease Pharmaceuticals Market Report |
||||||
最新發布
"濕性視網膜病變治療市場 (2025)" 報告包含多項更新和新見解，旨在更清晰地描繪未來五年的市場動態、競爭定位和成長機會。
新增內容包括更新的抗VEGF藥物疾病預測以及依活性成分修訂的銷售預測。我們也分析了Lucentis美國價格暴跌的影響，並追蹤了不同適應症的抗VEGF療法的市場佔有率。
此外，本報告還深入介紹了處於開發階段的項目，並提供了有關在研療法和新型作用機制的最新資訊。這些改進旨在更清晰地描繪未來五年的市場動態、競爭定位和成長機會。
本報告對濕性視網膜疾病療法進行了全面分析。本報告重點介紹了主要的市場趨勢、成長動力和未來機遇，並提供了眼科抗VEGF藥物品牌、非適應症抗癌藥物、生物相似藥和持續給藥裝置的五年預測（以單位和美元為單位）。該報告還按產品類別部門了市場佔有率，並詳細介紹了29家主要競爭對手的產品、策略和市場定位。
目錄
"濕性視網膜疾病治療市場（2025）報告" 全面介紹了針對濕性AMD和其他滲出性視網膜疾病的藥物市場。本報告旨在為讀者提供深入的背景信息，涵蓋了對疾病的全方位理解、治療方案和市場動態。
涵蓋的關鍵領域包括：
- 疾病概況：疾病概況：視網膜疾病及其危險因子、診斷與治療趨勢。
- 全球視野：視網膜專科醫師的治療模式與主要市場。
- 目前治療方法：已上市的治療濕性視網膜疾病的藥物和生物製劑。
- 研發管線洞察：正在開發中的跨多種作用機制的在研藥物。
- 競爭格局：擁有商業化療法的公司以及開展臨床前研究計畫的公司概況。
- 詳細市場預測：品牌眼科抗VEGF藥物、非適應症抗癌藥物、濕性視網膜疾病的生物相似藥及持續給藥裝置。
該報告也分析了八類藥物的研發管線。
|
|
這種系統性的方法使讀者能夠清楚地了解滲出性視網膜疾病領域的當前機會、新興趨勢和未來成長潛力。疾病。
What's New:
The "2025 Exudative Retinal Disease Pharmaceuticals Market Report" includes a number of updates and fresh insights to provide a clearer picture of market dynamics, competitive positioning, and growth opportunities in this segment over the next five years.
New features include updated disease forecasts and revised sales projections for anti-VEGFs, broken down by active agent. The report also examines the impact of collapsing US prices for Lucentis and tracks anti-VEGF treatment shares by disease indication.
In addition, the report provides a thorough update on development-stage programs, offering the latest on investigational therapies and emerging mechanisms of action. Together, these enhancements provide a clearer picture of market dynamics, competitive positioning, and growth opportunities for the next five years.
The "2025 Exudative Retinal Disease Pharmaceuticals Market Report" delivers a comprehensive analysis of anti-VEGFs and other therapies for exudative retinal diseases. It highlights key market trends, growth drivers, and future opportunities, with five-year forecasts in units and dollars for branded ocular anti-VEGFs, cancer drugs used off-label, biosimilars, and sustained-drug-delivery devices. The report also breaks down market share by product category and profiles 29 leading competitors, detailing their products, strategies, and market positioning.
Contents:
The "2025 Exudative Retinal Disease Pharmaceuticals Market Report" provides a comprehensive view of the market for therapies targeting wet AMD and other exudative retinal diseases. Designed to give readers both depth and context, the report covers the full spectrum of disease understanding, treatment options, and market dynamics.
Key areas of coverage include:
- Disease landscape: Retinal diseases and their risk factors, plus diagnosis and treatment trends.
- Global perspective: Retina specialists and patterns of care across major markets.
- Current therapies: Pharmaceuticals and biologics already on the market for exudative retinal diseases.
- Pipeline insights: Investigational agents under development, across multiple mechanisms of action.
- Competitive landscape: Profiles of companies marketing therapies, plus additional firms with preclinical programs.
- Detailed market forecasts for: Branded ocular anti-VEGFs, cancer drugs used off-label, biosimilars for exudative retinal diseases, and sustained-drug-delivery devices
The report also analyzes the development pipelines across eight pharmaceutical categories:
|
|
This structured approach gives readers a clear understanding of current opportunities, emerging trends, and future growth potential in the exudative retinal disease segment.
